US Tariff Cut to Boost India's AYUSH, Nutraceutical Exports: Industry Relief

The recent India-US interim trade deal has slashed US tariffs on Indian goods from 50% to 18%, providing immediate relief to the AYUSH and nutraceutical export sectors. Industry founder Lal Hingorani stated the high tariff was hitting the small-margin industry very hard, though pricing pressures from buyers remain a challenge. India's AYUSH and herbal product exports to the US, its largest market, were approximately $689 million in 2024-25, led by Ashwagandha and Turmeric. The framework is a first step toward a broader Bilateral Trade Agreement and includes addressing non-tariff barriers and supply chain resilience.

Key Points: US Tariff Cut Benefits India's AYUSH, Nutraceutical Sectors

  • US tariffs cut from 50% to 18%
  • AYUSH exports to US grew 6.11%
  • Top exports are Ashwagandha, Turmeric
  • Deal addresses non-tariff barriers
  • Part of broader trade agreement path
3 min read

US tariff cut to benefit India's AYUSH, nutraceutical sectors under interim trade deal: Pharmanza Herbal Founder

India's AYUSH & nutraceutical exports to get major boost as US slashes tariffs from 50% to 18% under interim trade deal, says industry expert.

"With the reduction to 18 per cent, we will see a significant benefit - Lal Hingorani"

Ahmedabad, February 9

India's AYUSH and nutraceutical sectors are expected to see a significant boost following the reduction in US tariffs under the India-US Interim Trade Deal, Founder & Director of Pharmanza Herbal Pvt Ltd, Lal Hingorani, said in an exclusive conversation with.

Commenting on the development, Hingorani said the industry had been under severe pressure due to high tariffs and low operating margins.

"People were waiting for this change. Our industry, particularly the AYUSH and nutraceutical sectors, was affected because it is very small and margins are limited. A 50 per cent tariff was hitting us really hard," he said.

He added that the reduction in tariffs to 18 per cent would bring immediate relief to exporters. "With the reduction to 18 per cent, we will see a significant benefit, but we still expect it to return to the normal level that existed before," Hingorani noted.

Highlighting sector-specific challenges, he pointed out that pricing pressures remain a key concern. "One factor specific to our industry is pricing. Buyers were demanding very low prices, but given the FDA regulations and other requirements, it is simply not possible to manufacture goods at those prices," he said.

AYUSH encompasses traditional systems of medicine such as Ayurveda, Yoga, Unani, Siddha, and Homeopathy.

According to data from the Ministry of AYUSH, the Ayurveda Export Promotion Council (AYUSHEXCIL), and trade analysis, India's AYUSH and herbal product exports to the US stood at approximately USD 688.89 million in 2024-25, registering a growth of 6.11 per cent.

The US remains the largest market for Indian AYUSH and herbal products, accounting for a significant share of total exports.

The top exported products include Ashwagandha, which leads the list, followed by Turmeric, Ginger, Neem, Triphala, Tulsi, Brahmi, and Shatavari. Key export components comprise Ayurvedic products, Unani, Siddha, Sowa Rigpa medicines, and a wide range of herbal supplements.

India and the US announced the interim trade deal framework in a joint statement on February 6, 2026. The framework is positioned as the first step towards a broader Bilateral Trade Agreement (BTA).

Under the arrangement, the US will apply a reciprocal tariff rate of 18 per cent on Indian goods and has outlined a path for the removal of reciprocal tariffs on a wider set of products if the Interim Trade Agreement (ITA) is successfully concluded.

Beyond tariff reductions, both countries have agreed to address non-tariff barriers, establish rules of origin, strengthen supply chain resilience, and work towards ambitious digital trade rules as part of the proposed BTA.

The US has also legally withdrawn the additional 25 per cent ad valorem duty under Executive Order 14329, effective February 7, 2026, providing further relief to Indian exporters.

- ANI

Share this article:

Reader Comments

R
Rohit P
Good step, but 18% is still high no? The article says they want it back to "normal level that existed before". What was that rate? Government should negotiate harder for our MSMEs in this sector. Many small manufacturers in Gujarat and Kerala will benefit if margins improve.
A
Arjun K
As someone in the export business, I can confirm the pressure was immense. A 50% tariff was killing us. This interim deal is a lifeline. The focus now must be on quality control and branding so 'Made in India' AYUSH products command premium prices, not just low-cost ones.
S
Sarah B
Interesting development. From a US consumer perspective, more access to authentic Ayurvedic supplements at better prices is welcome. But the point about FDA regulations is key. Hope this encourages stricter quality standards on the Indian side too, ensuring safety and efficacy.
V
Vikram M
$688 million exports is just the beginning! Imagine the potential if we properly market our Yoga and wellness tourism alongside these products. This sector can create so many rural jobs in herb cultivation and processing. Jai AYUSH! 🙏
K
Karthik V
While the tariff cut helps, the real issue is the "non-tariff barriers" mentioned. Western countries often use complex regulations as hidden trade walls. Our diplomats and industry bodies need to work continuously to simplify these for our exporters. The deal is a good first step.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50